Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?